Status:
COMPLETED
Impact of Sodium Glucose Co-transporter 2-Inhibitors on Clinical Outcome and Left Ventricular Function in Patients Presented by Acute Myocardial Infarction
Lead Sponsor:
Tanta University
Conditions:
Sodium-glucose Cotransporter 2
Inhibitors
Eligibility:
All Genders
18+ years
Brief Summary
This study aimed to assess the effect of adding sodium glucose co-transporter two inhibitors on clinical outcome and left ventricular function in patients with acute myocardial Infarction.
Detailed Description
Sodium-glucose co-transporter-2 (SGLT-2) inhibitors are a class of anti-hyperglycemic agents that act on the SGLT-2 proteins expressed in the renal proximal convoluted tubules. They exert their effect...
Eligibility Criteria
Inclusion
- Age ≥ 18 years.
- Both sexes.
- Recent myocardial infarction.
- Evidence of significant myocardial necrosis defined as a rise in troponin level \> 99th Percentile ULN (upper limit of normal). In addition, at least one of the following criteria must be met:
- Symptoms of ischemia.
- ECG changes indicative of new ischemia (new ST-T changes or new Left bundle branch block (LBBB))
- Imaging evidence of new regional wall motion abnormality.
- Estimated Glomerular Filtration Rate (eGFR)\> 30 ml/min/1.73 m2.
- Blood pressure before first drug dosing \>110/70 mmHg.
Exclusion
- Known allergy to sodium/glucose cotransporter 2 (SGLT2) inhibitors.
- Patients with poor echocardiographic views.
- Hemodynamic instability as defined by intravenous administration of catecholamine.
- \>1 episode of severe hypoglycemia within the last 6 months under treatment with insulin or sulfonylurea.
- Pregnant women or females of childbearing age without adequate contraceptive methods.
- Acute symptomatic urinary tract infection (UTI) or genital infection
- Patients currently being treated with any SGLT-2 inhibitor or having received treatment with any SGLT-2 inhibitor within the 4 weeks before the screening visit.
- Patient with a previous myocardial ischemic event or previous heart failure.
- Patients with significant valvular dysfunction.
Key Trial Info
Start Date :
April 1 2023
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
April 1 2024
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT06964607
Start Date
April 1 2023
End Date
April 1 2024
Last Update
May 9 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Tanta University
Tanta, El-Gharbia, Egypt, 31527